SHINE closes $50M in financing to support isotope production

Matt O'Connor | | Health Imaging | Molecular Imaging

SHINE Medical Technologies announced Tuesday, that it has secured $50 million in financing to support construction of its medical isotope production facility.

The funds, managed by Oaktree Capital Management, will support SHINE’s commercialization of molybdenum-99 and lutetium-177 (Lu-177) in addition to construction of the physical production facility.

The Janesville, Wisconsin-based company plans to have its plant completed in 2021, with “commercial-scale” isotope production kicking-off in 2022.

“Oaktree and Deerfield will help us deliver on SHINE’s value proposition, including the completion of our isotope production facility and the development of our therapeutics business,” Greg Piefer, founder and CEO of SHINE, said in a news release. “Their participation validates the strength of our business case, team and vision for bringing our lifesaving products to market.”

Back in August, former House Speaker Paul Ryan joined the SHINE board of directors. And in May, the company gained an exclusive intellectual property license to produce Lu-177.

""
Matt O'Connor

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business
FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup